Development and evaluation of a tetravalent botulinum vaccine

References

• Rossetto O, Montecucco C. Tables of Toxicity of Botulinum and Tetanus Neurotoxins Toxins 2019;11(12):686. doi:10.3390/toxins11120686.
   Google Scholar
• Hill KK, Smith TJ, Helma CH, Ticknor LO, Foley BT, Svensson RT, Brown JL, Johnson EA, Smith LA, Okinaka RT, et al. Genetic diversity among Botulinum Neurotoxin-producing clostridial strains. J Bacteriol. 2007;189(3):818–8. doi:10.1128/jb.01180-06.
   PubMed Web of Science ®Google Scholar
• Tehran DA, Pirazzini M. Novel botulinum neurotoxins: exploring underneath the iceberg tip. Toxins. 2018;10(5):10. doi:10.3390/toxins10050190.
   Web of Science ®Google Scholar
• Dembek ZF, Smith LA, Rusnak JM. Botulism: cause, effects, diagnosis, clinical and laboratory identification, and treatment modalities. Disaster Med Public Health Prep. 2007;1(2):122–34. doi:10.1097/DMP.0b013e318158c5fd.
   PubMed Web of Science ®Google Scholar
• Smith LA. Botulism and vaccines for its prevention. Vaccine. 2009;27(Suppl 4):D33–9. doi:10.1016/j.vaccine.2009.08.059.
   PubMed Web of Science ®Google Scholar
• Pirazzini M, Rossetto O, Eleopra R, Montecucco C. Botulinum neurotoxins: biology, pharmacology, and toxicology. Pharmacol Rev. 2017;69(2):200–35. doi:10.1124/pr.116.012658.
   PubMed Web of Science ®Google Scholar
• Sinha J, Inan M, Fanders S, Taoka S, Gouthro M, Swanson T, Barent R, Barthuli A, Loveless BM, Smith LA, et al. Cell bank characterization and fermentation optimization for production of recombinant heavy chain C-terminal fragment of botulinum neurotoxin serotype E (rBonte(hc): Antigen E) by Pichia pastoris. J Biotechnol. 2007;127(3):462–74. doi:10.1016/j.jbiotec.2006.07.022.
   PubMed Web of Science ®Google Scholar
• Shukla HD, Sharma SK. Clostridium botulinum: a bug with beauty and weapon. Crit Rev Microbiol. 2005;31(1):11–18. doi:10.1080/10408410590912952.
   PubMed Web of Science ®Google Scholar
• Sundeen G, Barbieri JT. Vaccines against botulism. Toxins. 2017;9(9):26. doi:10.3390/toxins9090268.
   PubMed Web of Science ®Google Scholar
• Webb RP, Smith LA. What next for botulism vaccine development? Expert Rev Vaccines. 2013;12(5):481–92. doi:10.1586/ERV.13.37.
   PubMed Web of Science ®Google Scholar
• Lou J, Marks JD. Botulinum Neurotoxins (BoNTs)-antibody and vaccine. Toxins 2018;10(12):495. doi:10.3390/toxins10120495.
   Web of Science ®Google Scholar
• Webb RP, Smith TJ, Smith LA, Wright PM, Guernieri RL, Brown JL, Skerry JC. Recombinant Botulinum Neurotoxin Hc Subunit (BoNT Hc) and Catalytically Inactive Clostridium botulinum Holoproteins (ciBont HPs) as vaccine candidates for the prevention of botulism. Toxins. 2017;9(9):9. doi:10.3390/toxins9090269.
   Web of Science ®Google Scholar
• Zichel R, Mimran A, Keren A, Barnea A, Steinberger-Levy I, Marcus D, Turgeman A, Reuveny S. Efficacy of a potential trivalent vaccine based on Hc fragments of botulinum toxins A, B, and E produced in a cell-free expression system. Clin Vaccine Immunol. 2010;17(5):784–92. doi:10.1128/CVI.00496-09.
   PubMedGoogle Scholar
• Moreira G, Cunha C, Salvarani F, Gonçalves L, Pires P, Conceição F, Lobato F. Production of recombinant botulism antigens: A review of expression systems. Anaerobe. 2014;28:130–36. doi:10.1016/j.anaerobe.2014.06.003.
   PubMed Web of Science ®Google Scholar
• Shearer JD, Manetz TS, House RV. Preclinical safety assessment of recombinant botulinum vaccine A/B (rBV A/B). Vaccine. 2012;30(11):1917–26. doi:10.1016/j.vaccine.2012.01.035.
   PubMed Web of Science ®Google Scholar
• Rasetti-Escargueil C, Popoff MR. Antibodies and vaccines against botulinum toxins: available measures and novel approaches. Toxins. 2019:11. doi:10.3390/toxins11090528.
   Web of Science ®Google Scholar
• Khouri JM, Motter RN, Arnon SS. Safety and immunogenicity of investigational recombinant botulinum vaccine, rBV A/B, in volunteers with pre-existing botulinum toxoid immunity. Vaccine. 2018;36(15):2041–48. doi:10.1016/j.vaccine.2018.02.042.
   PubMed Web of Science ®Google Scholar
• Yu YZ, Na L, Zhu HQ, Wang RL, Yun D, Shuang W, Yu WY, Sun ZW. The recombinant Hc subunit of Clostridium botulinum neurotoxin serotype A is an effective botulism vaccine candidate. Vaccine. 2009;27(21):2816–22. doi:10.1016/j.vaccine.2009.02.091.
   PubMed Web of Science ®Google Scholar
• Liu B, Shi D, Chang S, Gong X, Yu Y, Sun Z, Wu J. Characterization and immunological activity of different forms of recombinant secreted Hc of botulinum neurotoxin serotype B products expressed in yeast. Sci Rep. 2015;5:7678. doi:10.1038/srep07678.
   PubMed Web of Science ®Google Scholar
• Shi DY, Liu FJ, Mao YY, Cui RT, Lu JS, Yu YZ, Dong XJ, Yang ZX, Sun ZW, Pang XB. Development and evaluation of candidate subunit vaccine and novel antitoxin against botulinum neurotoxin serotype E. Hum Vaccin Immunother. 2020;16:100–08. doi:10.1080/21645515.2019.1633878.
   PubMed Web of Science ®Google Scholar
• Yu YZ, Li N, Wang RL, Zhu HQ, Wang S, Yu WY, Sun ZW. Evaluation of a recombinant Hc of clostridium botulinum neurotoxin serotype F as an effective subunit vaccine. Clin Vaccine Immunol CVI. 2008;15:1819. doi:10.1128/CVI.00239-08.
   PubMed Web of Science ®Google Scholar
• Vessely C, Estey T, Randolph TW, Henderson I, Nayar R, Carpenter JF. Effects of solution conditions and surface chemistry on the adsorption of three recombinant botulinum neurotoxin antigens to aluminum salt adjuvants. J Pharm Sci. 2007;96:2375–89. doi:10.1002/jps.20880.
   PubMed Web of Science ®Google Scholar
• Kissmann J, Ausar SF, Rudolph A, Braun C, Cape SP, Sievers RE, Federspiel MJ, Joshi SB, Middaugh CR. Stabilization of measles virus for vaccine formulation. Hum Vaccin. 2008;4:350–59. doi:10.4161/hv.4.5.5863.
   PubMed Web of Science ®Google Scholar
• Vessely C, Estey T, Randolph TW, Henderson I, Cooper J, Nayar R, Braun LJ, Carpenter JF. Stability of a trivalent recombinant protein vaccine formulation against botulinum neurotoxin during storage in aqueous solution. J Pharm Sci. 2009;98:2970–93. doi:10.1002/jps.21498.
   PubMed Web of Science ®Google Scholar
• Clark HF, Burke CJ, Volkin DB, Offit P, Ward RL, Bresee JS, Dennehy P, Gooch WM, Malacaman E, Matson D, et al. Safety, immunogenicity and efficacy in healthy infants of G1 and G2 human reassortant rotavirus vaccine in a new stabilizer/buffer liquid formulation. Pediatr Infect Dis J. 2003;22(10):914–20. doi:10.1097/01.inf.0000091887.48999.77.
   PubMed Web of Science ®Google Scholar
• Torii Y, Tokumaru Y, Kawaguchi S, Izumi N, Maruyama S, Mukamoto M, Kozaki S, Takahashi M. Production and immunogenic efficacy of botulinum tetravalent (A, B, E, F) toxoid. Vaccine. 2002;20(19–20):2556–61. doi:10.1016/s0264-410x(02)00157-3.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). MMWR Morb Mortal Wkly Rep. 2011 Notice of CDC’s discontinuation of investigational pentavalent (ABCDE) botulinum toxoid vaccine for workers at risk for occupational exposure to botulinum toxins. MMWR Morb Mortal Wkly Rep. 2011;60:1454–55.
   PubMedGoogle Scholar